News

Our members’ posters at SFN 2019

News

16.10.2019

In addition to our booth #866 on the exhibition floor, several of Neuroservices-Alliance members will be presenting posters during SfN Conference next eek in Chicago!

Read the program below for more information on sessions.

OCTOBER 19

2PM – ANABIOS

056.22 / J34 – Ex vivo human models of extracellular acidification in inflammatory pain states for enabling translational research and drug discovery

A.-T. TON, T. INDERSMITTEN, P. RATCHADA, K. SWEAT, G. PAGE, P. MILLER, A. GHETTI; Anabios Corp., San Diego, CA

See full description here

3PM – E-PHYS

055.15 / J2 – Differential sensitization of lamina I and III-V spinoparabrachial (SPB) neurons in anesthetized mice in chronic inflammatory condition

J. ALLARD;
E-Phys, Clermont-Ferrand, France

See full description here 

OCTOBER 21

11AM – KEY-OBS / NEUROSERVICE / TAKEDA

280.20 / B21 – Assessment of spine density and brain morphological phenotype in three rodent models of neurodevelopmental psychiatric disorders, poly(I:C): two-hit poly(I:C); and prenatal MAM rat model

Authors*D. RADL1, J.-C. BIZOT2, S. DAVID2, J. COMBEAU2, F. MASSE2, Y. OBAYASHI1, N. CHEN1, P. O’DONNELL3, R. PETROSKI4, O. TOURY4, B. BUISSON4, R. HODGSON1; 1Takeda California, San Diego, CA; 2Key-Obs, Orleans, France; 3Takeda Pharmaceuticals, Cambridge, MA; 4Neuroservice, Aix En Provence Cedex 3, France

See full description here

1PM – MOTAC Neuroscience

382.08. Bridging the gap between prodromal and symptomatic phases of Parkinson’s disease using translational EEG biomarkers in preclinical models

*V. DUVEAU1, J. VOLLE2, G. PORRAS3, E. PIOLI3, A. EVRARD1, C. RUGGIERO1, C. ROUCARD1, E. BEZARD4,3, Y. ROCHE1; 
1Synapcell SAS, Saint Ismier, France; 2SynapCell SAS, Saint Ismier, France; 3Motac Neurosci., Manchester, United Kingdom; 4Inst. of Neurodegenerative Dis., Bordeaux, France

See full description here

OCTOBER 23

8AM – MOTAC Neuroscience

653.01. µ Opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease

*E. Y. PIOLI1, Q. LI1, H. HULME2, E. FRIDJONSDOTTIR2, A. NILSSON2, P. ANDREN2, A. CROSSMAN1, E. BEZARD3; 
1MOTAC, Manchester, United Kingdom; 2Uppsala Univ., Uppsala, Sweden; 3Inst. of Neurodegenerative Dis., Bordeaux, France

See full description here 

10 AM – MOTAC Neuroscience

653.15. Effects of nociceptin/orphanin FQ (NOP) receptor antagonism with BTRX-246040 in animal models of Parkinson’s disease

*T. L. WALLACE1, E. BEZARD2,3, E. PIOLI3, W. J. MARTIN1; 
1Blackthorn Therapeut., San Francisco, CA; 2Inst. of Neurodegenerative Dis., Bordeaux, France; 3Motac Neurosci., Manchester, United Kingdo

See full description here

1PM – MOTAC Neuroscience / IMN

742.01. Characterization of Lewy bodies-induced neurodegeneration and synucleopathy in wild-type mice

*E. BEZARD1, L. ZHANG2, X. YU2, X. SUN2, W. ZHAO2, M. WANG2, X. LI2, Y. ZHANG2, T. ZHU2, L. ZHOU2, G. RAN2, L. BREGER1, S. DOVERO1, M. PERSILLET1, G. PORRAS1, P.-O. FERNAGUT1, B. DEHAY1, C. QIN2;
1Inst. of Neurodegenerative Dis., Bordeaux, France; 2Inst. of Lab. Animal Sci., Beijing, China

See full description here

3PM – MOTAC Neuroscience / IMN

742.03. High content screening of synucleinopathy in primary cortical neurons: Dissecting out the interplay between the basic synuclein pools

*W. MEISSNER, F. DE GIORGI, E. BEZARD, F. ICHAS;
Inst. of Neurodegenerative Dis., Bordeaux, France

See full description here

3PM – MOTAC Neuroscience / IMN

742.02. Sleep/wake activity in the Lewy bodies mouse model of Parkinson’s disease

*G. PORRAS¹, M. PERSILLET², F. DECOEUR³, B. DEHAY², A. NADJAR³, E. BEZARD²; 
¹Motac, Manchester, United Kingdom; ²Inst. of Neurodegenerative Dis., Bordeaux, France; ³Univ. of Bordeaux, Bordeaux, France

See full description

4PM – MOTAC Neuroscience / IMN

742.04. GCI-induced neurodegeneration and synucleinopathy in non-human primates

M. TEIL1, S. DOVERO1, M.-L. AROTCARENA1, M. BOURDENX1, S. CAMUS1, G. PORRAS1, M.-L. THIOLAT1, N. KRUSE2, B. MOLLENHAUER2, I. TRIGO DAMAS3, C. ESTRADA4, N. GARCIA CARRILLO5, M. TRINIDAD HERRERO EZQUERRO4, P. DERKINDEREN6, M. VILA7, J. OBESO3, *B. DEHAY1, E. BEZARD1; 
1Inst. of Neurodegenerative Dis., Bordeaux, France; 2Univ. Med. Ctr. Goettingen, Inst. of Neuropathology, Paracelsus-Elena- Klinik, Kassel, Germany, Goettingen, Germany; 3HM CINAC, HM Puerta del Sur and CIBERNED and CEU-San Pablo Univ. Madrid, Madrid, Spain; 4Inst. of Res. on Aging, Sch. of Medicine, Univ. of Murcia, Clin. and Exptl. Neurosci. Unit, Sch. of Medicine, Biomed. Res. Inst. of Murcia (IMIB), Univ. of Murcia, Campus Mare Nostrum, Murcia, Spain; 5Ctr. Exptl. en Investigaciones Biomédica (CEIB), Univ. de Murcia, Murcia, Spain; 6CHU Nantes, Dept. of Neurol., Inserm, U1235, Nantes, France; 7Dept. of Biochem. and Mol. Biology, Autonomous Univ. of Barcelona, Neurodegenerative Dis. Res. Group, Vall d’Hebron Res. Inst., Barcelona, Spain

See full description 

Go back